Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
Condition: Restless Legs Syndrome
MeSH terms: Psychomotor Agitation; Restless Legs Syndrome; Syndrome
Intervention: ropinirole controlled release (CR)-RLS
Intervention description: White film-coated round-shaped tablet
Intervention MeSH terms: Ropinirole
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 35.0
Sex: All
Minimum age: 18 Years
Maximum age: 79 Years
Healthy volunteers: No
Keywords: Restless Legs Syndrome

Summary:

      This study was designed to evaluate the safety, pharmacokinetic profile and efficacy in
      Restless Legs Syndrome patients.
    

Eligibility criteria:

        Inclusion Criteria:

          -  A subject will be considered eligible for inclusion in this study only if all of the
             following criteria apply:

        At Week -1 (at the start of Screening period)

          -  Patients who are diagnosed with RLS according to the International RLS Study Group's
             (IRLSSG) Diagnostic Criteria.

          -  Age: Patients aged at least 18 years and under 80 years.

          -  Patients who have had RLS symptoms in the evening or nighttime (17:00 to 7:00 next
             day) for at least 20 days within one month before the start of the screening period.
             Patients treated for RLS before the start of the Screening period and who do not meet
             this criterion are considered eligible if the previous therapy can be discontinued
             from the Screening period.

          -  Patients who experience RLS symptoms requiring treatment after 17:00 but prior to
             bedtime.

          -  Gender: male and female Female of child-bearing potential will be eligible for
             inclusion in this study. However they must have a negative pregnancy test at the
             Screening visit. They agree are perform pregnancy test at the time determined and
             practice one of the following method of contraception from the Screening visit till
             the end of follow-up examination.

               -  Abstinence

               -  Oral Contraceptive, either combined or progestogen alone

               -  Injectable progestogen

               -  Implants of levonorgestrel

               -  Estrogenic vaginal ring

               -  Percutaneous contraceptive patches

               -  Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP
                  effectiveness criteria as stated in the product label

               -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to
                  the female subject's entry into the study, and this male is the sole partner for
                  that subject

               -  Double barrier method: condom or occlusive cap (diaphragm or cervical / vault
                  caps) plus spermicidal agent (foam /gel / film / cream / suppository

          -  Inpatient or outpatient status: Outpatient status

          -  Patients who are able to give informed written consent in person. For patients aged
             under 20 years, their legally acceptable representatives are able to give informed
             written consent.

        At Week 0 (at the start of treatment period)

          -  Patients who experience RLS symptoms in the evening and nighttime (17:00 to 7:00 next
             day) for at least 4 days within 7 days before the start of the treatment period.

          -  Patients who have sleep impairment associated with RLS. Patients who answered as 3
             (severe) or 4 (very severe) to Question 4 (Sleep disturbance) in the IRLS Rating Scale

          -  Patients whose IRLS Rating Scale total scores are 15 points or more.

        Exclusion Criteria:

          -  Patients requiring treatment for daytime RLS symptoms (7:00 to 17:00).

          -  Patients with signs of secondary RLS (e.g. chronic renal failure, iron-deficiency
             anemia, pregnancy, rheumatoid arthritis and Parkinson's disease).

          -  Patients whose serum ferritin level is <10 μg/L (ng/mL) at the start of Screening
             period.

          -  Patients with following sleep disorder not associated with RLS e.g. narcolepsy, sleep
             terror disorder, sleep walking disorder, breathing related sleep disorder (Patients
             with obvious apnea in nighttime sleeping when they do not have alcohol drinking or
             over 15 times/hour is used to a target for apnea hypopnea index,in which case to
             implement polysomnography), etc.

          -  Patients with complication of movement disorder (e.g. Parkinson's disease, dyskinesia,
             dystonia, etc.).

          -  Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic
             disorder.

        The severity refers to Grade 3 according to "the Classification of the Severity of Adverse
        Experiences" (Pharmaceutical affairs Bureau/Safety Division (PAB/SD) Notification No. 80,
        dated 29 June 1992).

          -  Patients with the medical history or complication of cancer or malignant tumour.

          -  Patients with the medical history or complication of substance abuse (e.g. alcohol or
             drug) or dependency of substance for the last one year

          -  Patients whose diastolic blood pressure (BP) is >110 mmHg or <50 mmHg or whose
             systolic BP is >180 mmHg or <90 mmHg at the start of Screening period and Week0.

          -  Patients intolerant for ropinirole hydrochloride (HCl) or other dopamine agonists.

          -  Patients with the medical history of allergy to ropinirole HCl in the past.

          -  Patients with the medical history of Augmentation to ropinirole HCl or other dopamine
             agonists in the past and those who have experienced early morning RLS symptoms.

        Augmentation is defined as below:

        RLS appear 2 hours earlier than the pre-treatment. Symptoms become severer than the
        pre-treatment. Symptoms which start after less time at rest than they did before treatment.
        The RLS extend to other sites (e.g. arm and trunk).

          -  Patients without nighttime sleeping habit (e.g. night-shift worker, etc.) and those
             who must drastically change the habitual bedtime during the study duration.

          -  Patients who have participated in another clinical study of an investigational product
             or medical device within the last 12 weeks prior to the start of screening period.

          -  Female patients who are pregnant or lactating, who may be pregnant, or who plan for
             pregnancy during the study .

          -  Patients with chronic hepatitis typeB and /or typeC which is positive of hepatitis B
             surface antigen （HBsAg）and/or hepatitis C antibody.

          -  Patients who have medical conditions which, in the opinion of investigator could
             affect efficacy and safety assessment. This may include, but are not limited to the
             following disorders: diabetes, peripheral neuropathy, fibromyalgia syndrome,
             symptomatic orthostatic hypotension, hepatic or renal failure, pleuro-pulmonary
             fibrosis.

          -  Patients who have received treatment of an estrogen drug product and a drug that are
             known to substantially inhibit CYP1A2 and have changed the dose from baseline visit to
             Week 0.

          -  Others whom the investigator (sub investigator) considers ineligible for the study.